Cargando…
Composite cognitive and functional measures for early stage Alzheimer's disease trials
INTRODUCTION: Composite scales have been advanced as primary outcomes in early stage Alzheimer's disease trials, and endorsed by the U.S. Food and Drug Administration (FDA) for pivotal trials. They are generally composed of several neurocognitive subscales and may include clinical and functiona...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233425/ https://www.ncbi.nlm.nih.gov/pubmed/32432155 http://dx.doi.org/10.1002/dad2.12017 |